Bausch & Lomb Inc. and Technolas Perfect Vision GmbH have passed a U.S. regulatory hurdle for Victus femtosecond lasers, receiving Food and Drug Administration 501(k) clearance for the surgical devices.
The companies plan to start placing Victus lasers with U.S. surgery centers, eye-care company officials said Monday.
Victus lasers are eye-surgery devices for performing cataract operations and corneal surgeries. Femtosecond lasers emit quadrillionth of a second-long pulses. The extremely short duration is supposed to greatly minimize trauma to eye tissue and allow eye surgeons to make more precise incisions.
Bausch & Lomb inked a worldwide joint marketing agreement last March with Technolas, a joint venture between the eye-care company and Germany-based 20/10 Perfect Vision AG. In September, Bausch & Lomb inked a definitive agreement giving it an option to acquire Technolas.
“This FDA clearance further strengthens our relationship with (Technolas) and we look forward to bringing the power of the Victus femtosecond laser to the U.S,” said John Barr, president of Bausch & Lomb’s global surgical business.
(c) 2012 Rochester Business Journal. To obtain permission to reprint this article, call 585-546-8303 or e-mail email@example.com.